Deals channel feed

Mer­ck emerges as lead bid­der in po­ten­tial Ac­celeron buy­out with deal pos­si­ble this week — re­port

4 years ago
Pharma

Days of heat­ed ru­mors cul­mi­nate in a re­port that Ac­celeron is in ad­vanced buy­out talks

4 years ago
R&D

Till­man Gern­gross project out of Dart­mouth Col­lege ac­quired by Repli­gen

4 years ago
Manufacturing

As­traZeneca teams up with Im­pe­r­i­al off­shoot Vax­E­quity on an RNA 3.0 ef­fort

4 years ago
R&D

In­side look: How a po­ten­tial part­ner­ship turned in­to a $1.9B buy­out for Sanofi

4 years ago

Div­ing deep­er in­to in­her­it­ed reti­nal dis­or­ders, No­var­tis gob­bles up an­oth­er bite-sized op­to­ge­net­ics biotech

4 years ago
Cell/Gene Tx

Chi­nese biotech Ever­est signs $550M+ li­cens­ing deal for BTK in­hibitors on heels of Covid-19 pact

4 years ago
China

Gri­fols drops $1B on Ger­man hold­ing com­pa­ny in con­tin­ued plas­ma push

4 years ago

No­vo Nordisk Foun­da­tion tees up $47.5M to ex­plore the dri­vers of ge­net­ic dis­ease with the Broad In­sti­tute

4 years ago

For­mer Shkre­li com­pa­ny Tra­vere lands li­cens­ing deal with Vi­for on kid­ney drug

4 years ago

Look­ing for the next mR­NA break­through, Mod­er­na taps Ab­Cellera in mys­te­ri­ous an­ti­body dis­cov­ery deal

4 years ago
Discovery
Cell/Gene Tx

Ser­vices firm Mesa buys out mol­e­c­u­lar di­ag­nos­tics play­er for a cool $300M as ge­net­ics test­ing gains steam

4 years ago

How Jan Skvar­ka and Tril­li­um went from down and out to buy­out with Pfiz­er

4 years ago

Se­r­i­al en­tre­pre­neur Gary Glick sells an­oth­er one of his star­tups for $229M — this time to an un­like­ly buy­er

4 years ago

Trans-Pa­cif­ic pow­er play­er Ever­est jumps on mR­NA vac­cine deal with Prov­i­dence, pay­ing $100M up­front to tap plat­form play

4 years ago
China

Ab­b­Vie dives deep­er in­to eye care, pay­ing $370M cash — with a $1.4B sweet­en­er — to part­ner on VEGF gene ther­a­py

4 years ago

Boehringer In­gel­heim taps a pop­u­lar an­ti­body dis­cov­ery play­er for ac­cess to drug 'li­brary of li­braries'

4 years ago

Io­n­is col­lab­o­ra­tor Flamin­go is ready to take flight with 3 an­ti­sense drugs in the clin­ic and mys­te­ri­ous RNA in its sights

4 years ago
Startups

Eli Lil­ly bets on an RNA base edit­ing out­fit lever­ag­ing the body's own en­zymes to re­verse mu­ta­tions

4 years ago
Discovery

Months af­ter land­ing Cana­di­an site from gov­ern­ment, Re­silience an­nounces a big mR­NA part­ner

4 years ago
Manufacturing

Sanofi picks up Kad­mon and its trans­plant drug in $1.9B buy­out, giv­ing Sam Wak­sal 2 Big Phar­ma buy­outs un­der his belt

4 years ago

Mer­ck KGaA en­trusts se­cre­tive start­up with a mid-stage can­cer drug tar­get­ing mas­ter sig­nal­ing path­way

4 years ago

Years af­ter Pfiz­er passed on a buy­out op­tion, AM-Phar­ma finds a new part­ner for its kid­ney drug

4 years ago

Mov­ing on from a ma­jor set­back, Roche lines up a new Hunt­ing­ton's pro­gram for gene ther­a­py sub Spark

4 years ago
R&D
First page Previous page 69707172737475 Next page Last page
A service from the Financial Times